NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

Phase 2positiveNEO100Positive

AI Analysis

Summary

NeOnc Technologies announced positive topline Phase 2a results for intranasal NEO100 in patients with recurrent IDH1-mutant high-grade glioma. The positive data represents a meaningful milestone for the investigational therapy.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

Positive topline Phase 2a results

Importance:7/10

Sentiment:

0.80

phase 2agliomaIDH1-mutantintranasalpositive results

Read the original article

Published by GlobeNewswire Clinical Studies on August 12, 2026 12:00 PM

Read Original